NMR Lipoprofile
For informational purposes only — not medical advice. Always consult a qualified healthcare provider before making changes to your health regimen. Full disclaimer →
- LDL particle number (LDL-P) predicts cardiovascular risk better than LDL cholesterol in discordant patients. When LDL-C and LDL-P point in different directions — which happens in ~30% of people, particularly those with metabolic syndrome — LDL-P is the more accurate risk predictor. The MESA trial confirmed that LDL-P was a significantly stronger predictor of cardiovascular events than LDL-C after adjustment for other risk factors.
- Small dense LDL is the most atherogenic LDL subtype. Small, dense LDL particles are more atherogenic than large, buoyant LDL for several reasons: they penetrate the arterial endothelium more easily, are retained in the arterial wall longer, are more susceptible to oxidation, and have lower affinity for the LDL receptor (longer circulation time). High small LDL-P with normal total LDL-C is a pattern strongly associated with metabolic syndrome and insulin resistance.
- The LP-IR score is a validated insulin resistance index derived from the lipid panel. LP-IR uses six NMR-measured variables (VLDL size, large VLDL-P, large HDL-P, HDL size, LDL size, and small LDL-P) to estimate insulin resistance. It provides an insulin resistance assessment without a fasting insulin measurement and is validated against gold-standard euglycemic clamp insulin resistance measurements.
- NMR Lipoprofile is most valuable when standard lipid panels are misleading. People with normal LDL-C but high triglycerides and low HDL, people with low LDL-C on statin therapy who still have events, and people with metabolic syndrome are the highest-yield candidates for NMR Lipoprofile over standard panels.
- ApoB and NMR LDL-P are complementary, not interchangeable. ApoB is a simpler, cheaper, more widely validated measure of total atherogenic particle burden. NMR LDL-P adds particle size information and the LP-IR insulin resistance score. For most people, ApoB is the priority; NMR Lipoprofile adds incremental value in specific clinical contexts.
Why Counting LDL Particles Matters More Than Counting LDL Cholesterol
The standard lipid panel has served cardiovascular medicine for decades and continues to be the foundation of cardiovascular risk assessment. But it has a structural limitation: it measures the cholesterol content of lipoproteins rather than the lipoproteins themselves. This distinction — cargo versus carrier — is clinically meaningful because the cargo per carrier varies substantially between individuals and within the same individual under different metabolic conditions.
The analogy: imagine trying to assess highway congestion by measuring the total weight of all vehicles rather than counting the number of vehicles. Usually the two measures correlate. But if you have many small cars (small, cholesterol-poor LDL particles), total weight could be low while vehicle count is high — and vehicle count is what determines congestion (or in our case, arterial wall particle entry and plaque formation). NMR Lipoprofile counts the vehicles.
The clinical evidence for LDL particle number superiority in discordant cases is substantial. The MESA study — Multi-Ethnic Study of Atherosclerosis, a prospective cohort of 5,598 participants — found that LDL-P was a significantly stronger predictor of cardiovascular events than LDL-C after adjustment for other risk factors, and that in discordant individuals (high LDL-P / low LDL-C), LDL-P predicted events while LDL-C did not. 1
Understanding the NMR Lipoprofile Report
NMR Lipoprofile generates several outputs. Understanding what each measures helps prioritize which numbers to focus on:
LDL-P (LDL particle number): The total count of LDL particles, expressed in nmol/L. This is the primary metric — it correlates with ApoB (each LDL particle carries one ApoB) and is the strongest predictor of cardiovascular events on the NMR panel. Target below 700 nmol/L for longevity; below 1,000 nmol/L is the standard normal threshold.
Small LDL-P: The count of small, dense LDL particles specifically. This fraction is most atherogenic and is most elevated in metabolic syndrome. High small LDL-P with normal or low total LDL-P is unusual; more commonly, when small LDL-P is high, total LDL-P is also high. Small LDL-P responds well to carbohydrate restriction and triglyceride reduction.
LDL size: The average diameter of LDL particles. A lower number (smaller particles) indicates LDL pattern B — the metabolically unfavorable, more atherogenic pattern associated with insulin resistance. Improving metabolic health (reducing triglycerides, improving insulin sensitivity) shifts LDL size toward larger, less atherogenic particles.
HDL-P: HDL particle number. Analogous to LDL-P, this counts HDL particles rather than their cholesterol cargo. High HDL-P is associated with better cardiovascular outcomes than high HDL-C alone — it measures the functional capacity of the reverse cholesterol transport system more directly than HDL-C.
| Marker | Standard Threshold | Longevity Optimal | Notes |
|---|---|---|---|
| LDL-P (total) | < 1,000 nmol/L | < 700 nmol/L | Primary metric; correlates with ApoB |
| Small LDL-P | < 527 nmol/L | < 200 nmol/L | Most atherogenic LDL subfraction |
| LDL Size | > 20.5 nm | > 21.3 nm | Larger = Pattern A = less atherogenic |
| HDL-P | > 30.5 µmol/L | > 35 µmol/L | HDL particle count; more predictive than HDL-C |
| LP-IR Score | < 45 | < 25 | Insulin resistance index derived from NMR variables |
Already have your lab results? See how your NMR Lipoprofile markers score on a longevity scale — in under 60 seconds.
Analyze My Biomarkers →How to Improve NMR Lipoprofile Markers
The interventions that improve NMR Lipoprofile markers target the underlying metabolic drivers of atherogenic dyslipidemia — primarily insulin resistance and visceral adiposity.
Reducing refined carbohydrates and added sugars is the most effective dietary intervention for NMR markers. Carbohydrate restriction reduces VLDL production, which lowers triglycerides, raises HDL, and — critically — shifts LDL particles from small and dense (pattern B) to large and buoyant (pattern A). This dietary approach improves every NMR metric simultaneously and is often more effective than fat restriction for atherogenic dyslipidemia.
Improving insulin sensitivity through exercise, weight loss, and dietary improvement reduces the metabolic dyslipidemia that produces the discordant high LDL-P / normal LDL-C pattern. The LP-IR score normalizes with successful insulin resistance treatment.
Statin therapy primarily reduces LDL-C and LDL-P, with less effect on particle size or the metabolic dyslipidemia pattern. Statins are highly effective for reducing total LDL-P but do not address the small dense LDL phenotype as effectively as metabolic interventions or fibrates.
Omega-3 fatty acids at 2–4 g/day of EPA+DHA reduce VLDL production and triglycerides, which shifts LDL particles toward larger size. They are particularly effective for reducing the VLDL-driven component of atherogenic dyslipidemia.
Sources
- Otvos JD, et al. "Low-Density Lipoprotein and High-Density Lipoprotein Particle Subclasses Predict Coronary Events and Are Favorably Changed by Gemfibrozil Therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial." Circulation, 2002 / Mora S, et al. "LDL Particle Subclasses, LDL Particle Size, and Carotid Atherosclerosis in the Multi-Ethnic Study of Atherosclerosis." Atherosclerosis, 2007. PubMed →
| Range Type | Value (nmol/L (LDL-P), µmol/L (HDL-P)) | Notes |
|---|---|---|
| Standard Clinical Range | LDL-P: < 1,000 nmol/L (optimal) · Small LDL-P: < 527 nmol/L · HDL-P: > 30.5 µmol/L · LP-IR Score: < 45 | Designed to identify disease risk — not longevity optimisation. |
| Longevity-Optimal Target | LDL-P: < 700 nmol/L · Small LDL-P: < 200 nmol/L · HDL-P: > 35 µmol/L · LP-IR Score: < 25 |
Associated with reduced all-cause mortality and extended healthspan.
NMR Lipoprofile outputs are not directly comparable to ApoB — though LDL-P and ApoB measure conceptually similar things (particle number vs. particle-associated protein), they use different units and methods. ApoB counts all atherogenic particles (including VLDL and IDL) while LDL-P counts only LDL particles. For most clinical purposes, ApoB is a simpler and more widely validated single-number summary of atherogenic burden. NMR Lipoprofile adds value primarily through LDL particle size and the LP-IR insulin resistance score, which ApoB alone does not provide.
|
Already have your results? See what your NMR Lipoprofile and other markers reveal about your longevity in 60 seconds.
Analyze My Labs →Affiliate disclosure: we may earn a commission if you purchase through these links at no extra cost to you.
What is LDL discordance and why does it matter?
LDL discordance refers to cases where LDL cholesterol (LDL-C) and LDL particle number (LDL-P or ApoB) point in different directions. In most people LDL-C and LDL-P are concordant — both high or both low. But in approximately 20–30% of people, particularly those with low HDL, high triglycerides, insulin resistance, or metabolic syndrome, these measures diverge. The most clinically important pattern is high LDL-P with low or normal LDL-C — which occurs when someone has many small, cholesterol-poor LDL particles. Because each small LDL particle carries less cholesterol, total LDL-C is normal despite a high particle count. Standard lipid panels classify these people as low-risk (normal LDL-C), when they may actually be at elevated risk (high LDL-P). Multiple prospective studies including MESA have confirmed that in discordant cases, LDL-P is the more accurate predictor — meaning standard lipid panels systematically underestimate risk in this population.
How does NMR Lipoprofile compare to ApoB?
ApoB and NMR LDL-P measure similar but not identical things. ApoB is a protein — one molecule of ApoB is present on every atherogenic particle (LDL, VLDL, IDL, Lp(a)) — so ApoB counts the total number of all atherogenic particles. NMR LDL-P counts only LDL particles, missing the VLDL and IDL contribution. This means ApoB captures the complete atherogenic particle burden while LDL-P captures most of it (LDL is the dominant atherogenic particle in most adults). In practice, ApoB and LDL-P are very highly correlated and provide similar clinical information in most patients. ApoB is cheaper, simpler, and has a larger evidence base. NMR Lipoprofile adds value through its LDL particle size information (not available from ApoB alone) and the LP-IR score. For most patients, measuring ApoB is the priority; adding NMR Lipoprofile is appropriate when particle size and insulin resistance assessment are needed.
What does small dense LDL mean clinically?
LDL particles exist on a spectrum of sizes, from large and buoyant (pattern A) to small and dense (pattern B). The distinction matters because small dense LDL is more atherogenic than large LDL: small particles more easily penetrate the endothelial barrier into the arterial wall, are retained longer in the subintimal space, are more susceptible to oxidative modification (which triggers macrophage uptake and foam cell formation), and have reduced affinity for the LDL receptor (prolonging their circulation time and opportunity for arterial wall deposition). Small, dense LDL predominance — called LDL pattern B — is strongly associated with insulin resistance, metabolic syndrome, high triglycerides, and low HDL, forming the core of the 'metabolic dyslipidemia' or 'atherogenic dyslipidemia' phenotype. Standard LDL-C testing does not distinguish between large and small LDL particles — NMR Lipoprofile and Ion Mobility do.
Who benefits most from NMR Lipoprofile over a standard lipid panel?
The highest-yield candidates for NMR Lipoprofile: people with metabolic syndrome (high triglycerides, low HDL, central obesity, insulin resistance) — because this is where LDL discordance and small LDL predominance are most common; people on statin therapy who continue to have cardiovascular events despite apparently controlled LDL-C — NMR may reveal persistently elevated LDL-P despite low LDL-C; people with type 2 diabetes or prediabetes — the metabolic dyslipidemia of diabetes produces exactly the discordant pattern NMR is best at identifying; people with a strong family history of premature cardiovascular disease despite normal standard lipid panels; and people seeking the most comprehensive lipid risk assessment available. For a young, lean, metabolically healthy individual with a normal standard lipid panel, NMR Lipoprofile adds less incremental value.
What is the LP-IR score?
LP-IR (Lipoprotein Insulin Resistance) score is an index derived from six NMR-measured lipoprotein variables: VLDL particle size, large VLDL particle concentration, large HDL particle concentration, HDL particle size, LDL particle size, and small LDL particle concentration. These six variables are combined into a single score from 0–100, where higher scores indicate greater insulin resistance. LP-IR was validated against the euglycemic hyperinsulinemic clamp — the gold standard method for measuring insulin resistance — in multiple studies. It performs comparably to fasting insulin for insulin resistance assessment and significantly outperforms fasting glucose and HbA1c at detecting early insulin resistance. An LP-IR score below 25 is consistent with insulin sensitivity; above 45 suggests significant insulin resistance. LP-IR is particularly valuable because it provides an insulin resistance assessment without requiring a fasting insulin test — the LP-IR is calculated automatically when NMR Lipoprofile is ordered.